Cargando…

Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors

BACKGROUND: Pediatric brain tumors are the leading cause of cancer death in children with an urgent need for innovative therapies. Glypican 2 (GPC2) is a cell surface oncoprotein expressed in neuroblastoma for which targeted immunotherapies have been developed. This work aimed to characterize GPC2 e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foster, Jessica B, Griffin, Crystal, Rokita, Jo Lynne, Stern, Allison, Brimley, Cameron, Rathi, Komal, Lane, Maria V, Buongervino, Samantha N, Smith, Tiffany, Madsen, Peter J, Martinez, Daniel, Delaidelli, Alberto, Sorensen, Poul H, Wechsler-Reya, Robert J, Karikó, Katalin, Storm, Phillip B, Barrett, David M, Resnick, Adam C, Maris, John M, Bosse, Kristopher R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516314/ https://www.ncbi.nlm.nih.gov/pubmed/36167467 http://dx.doi.org/10.1136/jitc-2021-004450

Ejemplares similares

Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
por: Sun, Ming, et al.
Publicado: (2023)

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
por: Makkouk, Amani, et al.
Publicado: (2021)

IMMU-16. TARGETING GLYPICAN 2 (GPC2) ON PEDIATRIC MALIGNANT BRAIN TUMORS WITH MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2021)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
por: Zhang, Boning, et al.
Publicado: (2020)

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
por: Reppel, Loïc, et al.
Publicado: (2022)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
por: Amidi, Yalda, et al.
Publicado: (2022)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
por: Mancikova, Veronika, et al.
Publicado: (2020)

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
por: Johnson, P Connor, et al.
Publicado: (2022)

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

CD8(+) chimeric antigen receptor T cells manufactured in absence of CD4(+) cells exhibit hypofunctional phenotype
por: Lee, Sang Yun, et al.
Publicado: (2023)

Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
por: Jan, Chia-Ing, et al.
Publicado: (2021)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia
por: Trad, Rim, et al.
Publicado: (2022)

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
por: Lontos, Konstantinos, et al.
Publicado: (2023)

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
por: Qin, Haiying, et al.
Publicado: (2021)

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
por: Braun, Mitchell W, et al.
Publicado: (2020)

Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy
por: Zhang, Ping, et al.
Publicado: (2020)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation
por: Dragon, Anna Christina, et al.
Publicado: (2020)

PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction
por: Xia, Wenzheng, et al.
Publicado: (2020)

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
por: Gardell, Jennifer L, et al.
Publicado: (2020)

Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells
por: Bajwa, Gagan, et al.
Publicado: (2020)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
por: Adams, Sarah F, et al.
Publicado: (2020)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
por: Velasco-Hernandez, Talia, et al.
Publicado: (2020)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
por: Iida, Yuichi, et al.
Publicado: (2020)

HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
por: Chen, Alan Chen, et al.
Publicado: (2020)

Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages
por: Meziani, Lydia, et al.
Publicado: (2020)

Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
por: Kakimi, Kazuhiro, et al.
Publicado: (2020)

Neoantigen-specific CD4(+) T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy
por: Peng, Peng, et al.
Publicado: (2020)

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study
por: Verdegaal, Els, et al.
Publicado: (2020)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources
por: Schmidts, Andrea, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c64qhl6l8ua2bnimqlgs05cl7r